Cancer UrologyCancer UrologyОнкоурология1726-97761996-1812Publishing House ABV Press171510.17650/1726-9776-2024-20-1-153-163REVIEWSОБЗОРЫMetastatic castration-resistant prostate cancer and immune checkpoint inhibitorsМетастатический кастрационно-резистентный рак предстательной железы и ингибиторы иммунных контрольных точекhttps://orcid.org/0000-0002-2905-7735PavlovA. Yu.ПавловА. Ю.
Russian Federation

86 Profsoyuznaya St., Moscow 117997

Павлов Андрей Юрьевич - д.м.н., профессор, заместитель директора по научно лечебной работе.

117997 Москва, ул. Профсоюзная, 86

docgra@mail.ruhttps://orcid.org/0000-0001-5789-375XDzidzariaA. G.ДзидзарияА. Г.
Russian Federation

86 Profsoyuznaya St., Moscow 117997

Дзидзария Александр Гудисович - д.м.н., заведующий отделением онкоурологии.

117997 Москва, ул. Профсоюзная, 86

docgra@mail.ruhttps://orcid.org/0000-0002-7592-03922663-3760GafanovR. A.ГафановР. А.
Russian Federation

Rustem A. Gafanov.

86 Profsoyuznaya St., Moscow 117997

Гафанов Рустем Айратович - врач-онкоуролог, старший научный сотрудник научно-исследовательского отдела комплексной диагностики и лечения заболеваний органов мочеполовой системы у взрослых и детей, доцент отдела послевузовского образования.

117997 Москва, ул. Профсоюзная, 86

docgra@mail.ruhttps://orcid.org/0000-0003-1760-214XSamusevichV. A.СамусевичВ. A.
Russian Federation

86 Profsoyuznaya St., Moscow 117997

117997 Москва, ул. Профсоюзная, 86

https://orcid.org/0000-0001-7875-3756MirzoevE. E.МирзоевЭ. Э.
Russian Federation

86 Profsoyuznaya St., Moscow 117997

117997 Москва, ул. Профсоюзная, 86

https://orcid.org/0009-0004-5312-1495KortyshkovaA. O.КортышковаА. О.
Russian Federation

86 Profsoyuznaya St., Moscow 117997

117997 Москва, ул. Профсоюзная, 86

AivazovM. T.АйвазовМ. Т.
Russian Federation

86 Profsoyuznaya St., Moscow 117997

117997 Москва, ул. Профсоюзная, 86

MirzoevF. E.МирзоевФ. Э.
Russian Federation

86 Profsoyuznaya St., Moscow 117997

117997 Москва, ул. Профсоюзная, 86

Russian Scientific Center of Roentgenoradiology, Ministry of Health of RussiaФГБУ «Российский научный центр рентгенорадиологии» Минздрава России180520242011531631708202309042024https://oncourology.abvpress.ru/oncur/article/view/1715

Therapeutic landscape of several genitourinary malignancies has been revolutionized by the development of immune checkpoint inhibitors; however, the utility of immunotherapies in prostate cancer has been limited, partly due to the immunologically “cold” tumor microenvironment of prostate cancer. As of today, pembrolizumab is the only immune checkpoint inhibitor approved for treatment of metastatic castration-resistant prostate cancer (mCRPC) in a select group of patients with high microsatellite instability, deficient mismatch repair, or high tumor mutational burden. Currently, several combinations with immune checkpoint inhibitors involving radioligands, radiotherapy, PARP inhibitors, interleukin inhibitors, and cancer vaccines are being explored for potential synergistic effect. Furthermore, B7-H3 is an alternative checkpoint that may hold promise in treatment of mCRPC. This review aims to summarize previous monotherapy and combination therapy trials of immune checkpoint inhibitors as well as novel immunotherapy combinations and treatment targets in mCRPC.

Лекарственное лечение некоторых злокачественных новообразований мочеполовой системы претерпело революцию благодаря внедрению в клиническую практику ингибиторов иммунных контрольных точек. Однако применение иммунотерапии при раке предстательной железы несколько ограничено в связи с ее низкой эффективностью. На сегодняшний день пембролизумаб является единственным ингибитором иммунных контрольных точек, одобренным для лечения метастатического кастрационно-резистентного рака предстательной железы (мКРРПЖ) у пациентов с наличием микросателлитной нестабильности или высокой мутационной нагрузкой опухоли. В отношении некоторых комбинаций с ингибиторами иммунных контрольных точек, включающих радиолиганды, лучевую терапию, ингибиторы поли(АДФ-рибоза)-полимеразы, ингибиторы интерлейкина и противораковые вакцины, изучается потенциальный синергетический эффект. Контрольная точка иммунитета B7-H3 является альтернативной, которая может многообещающе дополнить схему лечения мКРРПЖ. Цель обзора – обобщить исследования ингибиторов иммунных контрольных точек в области монотерапии и комбинированной терапии, а также новые стратегии комбинированной иммунотерапии с определением целевых показателей лечения мКРРПЖ.

immune checkpoint inhibitormetastatic castration-resistant prostate cancercombinationimmunotherapyингибитор иммунных контрольных точекметастатический кастрационно-резистентный рак предстательной железыкомбинацияиммунотерапияSeer Cancer Statistics. Available at: https://seer.cancer.gov/statfacts/html/prost.html (accessed on 18 March 2023).Mitsogiannis I., Tzelves L., Dellis A. et al. Prostate cancer immunotherapy. Expert Opin Biol Ther 2022;22(5):577–90. DOI: 10.1080/14712598.2022.2027904Claps M., Mennitto A., Guadalupi V. et al. Immune-checkpoint inhibitors and metastatic prostate cancer therapy: learning by making mistakes. Cancer Treat Rev 2020 Aug;88:102057. DOI: 10.1016/j.ctrv.2020.102057Venkatachalam S., McFarland T.R., Agarwal N., Swami U. Immune checkpoint inhibitors in prostate cancer. Cancers (Basel) 2021;13(9):2187. DOI: 10.3390/cancers13092187Iannantuono G.M., Torino F., Rosenfeld R. et al. The role of histology-agnostic drugs in the treatment of metastatic castration-resistant prostate cancer. Int J Mol Sci 2022;23(15):8535. DOI: 10.3390/ijms23158535Pestana R.C., Sen S., Hobbs B.P., Hong D.S. Histology-agnostic drug development – considering issues beyond the tissue. Nat Rev Clin Oncol 2020;17(9):555–68. DOI: 10.1038/s41571-020-0384-0National Comprehensive Cancer Network Guideline Version 1.2023 Prostate Cancer. Available at: https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf (accessed on 18 March 2023).Marabelle A., Le D.T., Ascierto P.A. et al. Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/ mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 study. J Clin Oncol 2020;38(1):1–10. DOI: 10.1200/JCO.19.02105Le D.T., Uram J.N., Wang H. et al. PD-1 Blockade in tumors with mismatch-repair deficiency. N Engl J Med 2015;372(26):2509–20. DOI: 10.1056/NEJMoa1500596Antonarakis E.S., Piulats J.M., Gross-Goupil M. et al. Pembrolizumab for treatment-refractory metastatic castration-resistant prostate cancer: multicohort, open-label phase II KEYNOTE-199 study. J Clin Oncol 2020;38(5):395–405. DOI: 10.1200/JCO.19.01638Kwon E.D., Drake C.G., Scher H.I. et al. CA184-043 Investigators. Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol 2014;15(7):700–12. DOI: 10.1016/S1470-2045(14)70189-5Beer T.M., Kwon E.D., Drake C.G. et al. Double-blind, phase III trial of ipilimumab versus placebo in asymptomatic or minimally symptomatic patients with metastatic chemotherapy-naive castration-resistant prostate cancer. J Clin Oncol 2017;35(1):40–7. DOI: 10.1200/JCO.2016.69.1584Petrylak D.P., Loriot Y., Shaffer D.R. et al. Safety and clinical activity of atezolizumab in patients with metastatic castration-resistant prostate cancer: a phase I study. Clin Cancer Res 2021;27(12):3360–9. DOI: 10.1158/1078-0432.CCR-20-1981Topalian S.L., Hodi F.S., Brahmer J.R. et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012;366(26):2443–54. DOI: 10.1056/NEJMoa1200690Powles T., Yuen K.C., Gillessen S. et al. Atezolizumab with enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer: a randomized phase 3 trial. Nat Med 2022;28(1):144–53. DOI: 10.1038/s41591-021-01600-6Merck News Release. Available at: https://www.merck.com/news/merck-provides-update-on-phase-3-trials-keynote-641-and-keynote-789/ (accessed on 18 March 2023).Fizazi K., González Mella P., Castellano D. et al. Nivolumab plus docetaxel in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer: results from the phase II CheckMate 9KD trial. Eur J Cancer 2022;160:61–71. DOI: 10.1016/j.ejca.2021.09.043Fizazi K., Ulys A., Sengeløv L. et al. A randomized, double-blind, placebo-controlled phase II study of maintenance therapy with tasquinimod in patients with metastatic castration-resistant prostate cancer responsive to or stabilized during first-line docetaxel hemotherapy. Ann Oncol 2017;28(11):2741–6. DOI: 10.1093/annonc/mdx487Yu E.Y., Kolinsky M.P., Berry W.R. et al. Pembrolizumab plus docetaxel and prednisone in patients with metastatic castration-resistant prostate cancer: long-term results from the phase 1b/2 KEYNOTE-365 cohort B study. Eur Urol 2022;82(1):22–30. DOI: 10.1016/j.eururo.2022.02.023Petrylak D.P., Ratta R., Gafanov R. et al. KEYNOTE-921: phase III study of pembrolizumab plus docetaxel for metastatic castration-resistant prostate cancer. Future Oncol 2021;17(25):3291–9. DOI: 10.2217/fon-2020-1133Petrylak D.P., Ratta R., Matsubara N. et al. Pembrolizumab plus docetaxel for patients with metastatic castration-resistant prostate cancer (mCRPC): Randomized, double-blind, phase 3 KEYNOTE-921 study. J Clin Oncol 2023;41(6_suppl):19. DOI:10.1200/JCO.2023.41.6_suppl.19Sharma P., Pachynski R.K., Narayan V. et al. Nivolumab plus ipilimumab for metastatic castration-resistant prostate cancer: preliminary analysis of patients in the CheckMate 650 trial. Cancer Cell 2020;38(4):489–99.e3. DOI: 10.1016/j.ccell.2020.08.007Sharma P., Krainer M., Saad F. et al. Nivolumab plus ipilimumab for the treatment of post-chemotherapy metastatic castration-resistant prostate cancer (mCRPC): additional results from the randomized phase 2 CheckMate 650 trial. J Clin Oncol 2023;41(6_suppl). DOI: 10.1200/JCO.2023.41.6_suppl.22Heidegger I., Necchi A., Pircher A. et al. EAU-YAU Prostate Cancer Working Party. A systematic review of the emerging role of immune checkpoint inhibitors in metastatic castration-resistant prostate cancer: will combination strategies improve efficacy? Eur Urol Oncol 2021;4(5):745–54. DOI: 10.1016/j.euo.2020.10.010Chen X., Chen F., Ren Y. et al. IL-6 signaling contributes to radioresistance of prostate cancer through key DNA repair-associated molecules ATM, ATR, and BRCA 1/2. J Cancer Res Clin Oncol 2019;145(6):1471–84. DOI: 10.1007/s00432-019-02917-zMughees M., Kaushal J.B., Sharma G. et al. Chemokines and cytokines: axis and allies in prostate cancer pathogenesis. Semin Cancer Biol 2022;86(Pt 3):497–512. DOI: 10.1016/j.semcancer.2022.02.017Dorff T.B., Goldman B., Pinski J.K. et al. Clinical and correlative results of SWOG S0354: a phase II trial of CNTO328 (siltuximab), a monoclonal antibody against interleukin-6, in chemotherapy-pretreated patients with castration-resistant prostate cancer. Clin Cancer Res 2010;16(11):3028–34. DOI: 10.1158/1078-0432.CCR-09-3122Dorff T., Hirasawa Y., Acoba J. et al. Phase Ib study of patients with metastatic castrate-resistant prostate cancer treated with different sequencing regimens of atezolizumab and sipuleucel-T. J Immunother Cancer 2021;9(8):e002931. DOI: 10.1136/jitc-2021-002931De Bono J., Mateo J., Fizazi K. et al. Olaparib for metastatic castration-resistant prostate cancer. N Engl J Med 2020;382(22):2091–102. DOI: 10.1056/NEJMoa1911440Yu E.Y., Piulats J.M., Gravis G. et al. Pembrolizumab plus olaparib in patients with metastatic castration-resistant prostate cancer: long-term results from the phase 1b/2 KEYNOTE-365 cohort A study. Eur Urol 2023;83(1):15–26. (Erratum in: Eur Urol 2023;83(3):e87). DOI: 10.1016/j.eururo.2022.08.005LeVee A., Lin C.Y., Posadas E. et al. Clinical utility of olaparib in the treatment of metastatic castration-resistant prostate cancer: a review of current evidence and patient selection. Onco Targets Ther 2021;14:4819–32. (Erratum in: Onco Targets Ther 2021;14:5167–8). DOI: 10.2147/OTT.S315170ESMO Congress 2022 OncologyPro. Available at: https://oncologypro.esmo.org/meeting-resources/esmo-congress/pembrolizumab-olaparib-vs-abiraterone-abi-or-enzalutamideenza-for-patients-pts-with-previously-treated-metastaticcastration-resistant-pro (accessed on 18 March 2023).Karzai F., VanderWeele D., Madan R.A. et al. Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutations. J Immunother Cancer 2018;6(1):141. DOI: 10.1186/s40425-018-0463-2Bellavia M.C., Patel R.B., Anderson C.J. Combined targeted radiopharmaceutical therapy and immune checkpoint blockade: from preclinical advances to the clinic. J Nucl Med 2022;63(11):1636–41. DOI: 10.2967/jnumed.122.264373Sandhu S., Subramaniam S., Hofman M.S. et al. Evolution: phase II study of radionuclide 177 Lu-PSMA-617 therapy versus 177 Lu-PSMA-617 in combination with ipilimumab and nivolumab for men with metastatic castration-resistant prostate cancer (MCRPC; ANZUP 2001). J Clin Oncol 2023;41(6_suppl):TPS271. DOI: 10.1200/JCO.2023.41.6_suppl.TPS271Czernin J., Current K., Mona C.E. et al. 225Ac-PSMA617 efficacy in a mouse model of prostate cancer. J Nucl Med 2021;62(2):228–31. DOI: 10.2967/jnumed.120.246041Fong L., Morris M.J., Sartor O. et al. A phase Ib study of atezolizumab with radium-223 dichloride in men with metastatic castration-resistant prostate cancer. Clin Cancer Res 2021;27(17):4746–56. DOI: 10.1158/1078-0432.CCR-21-0063Shenderov E., Antonarakis E.S. B7-H3 and prostate cancer: new therapeutic dance partners. Eur Urol 2023;83(3):239–40. DOI: 10.1016/j.eururo.2022.10.019Benzon B., Zhao S., Haffner M. et al. Correlation of B7-H3 with androgen receptor, immune pathways and poor outcome in prostate cancer: an expression-based analysis. Prostate Cancer Prostatic Dis 2017;20:28–35. DOI: 10.1038/pcan.2016.49Guo C., Figueiredo I., Gurel B. et al. B7-H3 as a therapeutic target in advanced prostate cancer. Eur Urol 2023;83(3):224–38. (Erratum in: Eur Urol 2023;83(6):e168–9). DOI: 10.1016/j.eururo.2022.09.004Chapoval A., Ni J., Lau J. et al. B7-H3: a costimulatory molecule for T cell activation and IFN-γ production. Nat Immunol 2001;2:269–74. DOI: 10.1038/85339Kontos F., Michelakos T., Kurokawa T. et al. B7-H3: an attractive target for antibody-based immunotherapy. Clin Cancer Res 2021;27(5):1227–35. DOI: 10.1158/1078-0432.CCR-20-2584Mendes A.A., Lu J., Kaur H.B. et al. Association of B7-H3 expression with racial ancestry, immune cell density, and androgen receptor activation in prostate cancer. Cancer 2022;128(12):2269–80. DOI: 10.1002/cncr.34190Shenderov E., De Marzo A.M., Lotan T.L. et al. Neoadjuvant enoblituzumab in localized prostate cancer: a single-arm, phase 2 trial. Nat Med 2023;29(4):888–97. DOI: 10.1038/s41591-023-02284-wShi X., Day A., Bergom H.E. et al. Integrative molecular analyses define correlates of high B7-H3 expression in metastatic castrate-resistant prostate cancer. NPJ Precis Oncol 2022;6(1):80. DOI: 10.1038/s41698-022-00323-2Doi T., Patel M., Falchook G.S. et al. 453O DS-7300 (B7-H3 DXd Antibody-Drug Conjugate [ADC]) shows durable antitumor activity in advanced solid tumors: extended follow-up of a phase I/II study. Ann Oncol 2022;33:S744–5. DOI: 10.1016/j.annonc.2022.07.582Jang S., Powderly J.D., Spira A.I. et al. Phase 1 dose escalation study of MGC018, an Anti-B7-H3 Antibody-Drug Conjugate (ADC), in patients with advanced solid tumors. J Clin Oncol 2021;39(15_suppl):2631. DOI: 10.1200/JCO.2021.39.15_suppl.2631Miller J.S., Zorko N., Merino A. et al. 755P B7H3-targeted trispecific killer engagers deliver IL-15 to NK cells but not T-cells, and specifically target solid tumors as a pan-tumor antigen strategy mediated through NK cells. Ann Oncol 2022;33:S889. DOI: 10.1016/j.annonc.2022.07.881Zhang Y., He L., Sadagopan A. еt al. Targeting radiation-resistant prostate cancer stem cells by B7-H3 CAR T cells. Mol Cancer Ther 2021;20(3):577–88. DOI: 10.1158/1535-7163.MCT-20-0446Zorko N., Cichocki F., Goulding J. et al. Preclinical development of multiplexed-engineered IPSC-derived NK cells expressing a novel camelid nanobody Chimeric Antigen Receptor (CAR) targeting pan-cancer antigen B7-H3. Cancer Res 2022;82(Suppl_S12):2761(Abstract). DOI: 10.1158/1538-7445.AM2022-2761